Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with... Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0117 | -2.54016500217 | 0.4606 | 0.507 | 0.4005 | 60018 | 0.46275899 | CS |
| 4 | -0.3617 | -44.6212681964 | 0.8106 | 0.83 | 0.3642 | 168714 | 0.49101247 | CS |
| 12 | -0.2211 | -33 | 0.67 | 1.03 | 0.3642 | 828680 | 0.89769169 | CS |
| 26 | -0.7011 | -60.9652173913 | 1.15 | 1.5 | 0.3642 | 484940 | 0.88613472 | CS |
| 52 | -1.3811 | -75.4699453552 | 1.83 | 1.89 | 0.3642 | 352619 | 0.92368583 | CS |
| 156 | -2.5111 | -84.8344594595 | 2.96 | 3.25 | 0.3642 | 228335 | 1.16498075 | CS |
| 260 | -2.3411 | -83.9103942652 | 2.79 | 30.2 | 0.3642 | 476802 | 12.76644732 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
